Serva Energy Joins MedTech Accelerator Third Cohort
The Mayo Clinic and ASU MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, launched their third cohort on March 28, 2022. Arizona’s Serva Energy LLC, has been selected as one of the eight participants.
The accelerator provides emerging companies with a multi-day immersive curriculum in health care entrepreneurship including: lectures and workshops with world-class scientific and engineering experts; resources to navigate regulatory pathways; and tools for product commercialization and customer acquisition. Additionally, participants attend mentoring, business development, and networking events.
Serva Energy is a clean energy technology start-up based in Tempe, Arizona with the mission to transform our world through a new age of nuclear. Their technology is working to redesign the way radioisotopes and nuclear fuels are produced, serving the world with carbon-free solutions for critical health care solutions.
With a unique approach to nuclear, the company is considering nuclear waste as an asset rather than a problem. Their approach transforms massive amounts of transuranic waste into nuclear fuel, which then destroys itself as it generates power. Experimental validation is underway with a proof of concept expected by early 2023. Given the greater neutron economy of even lower-flux reactors, this method is expected to produce significantly higher levels than other existing or proposed methods.
A similar approach is used to accelerate the production of life-saving medical isotopes, like Actinium-225 – a promising cancer treatment known as the “rarest drug on earth”. Most of the existing supply has come from processing nuclear waste. With Serva Energy’s approach to harnessing nuclear waste, the company has identified a novel reactor-based production method for developing Actinium-225 using a proprietary fusion-fission hybrid process.
The research won’t stop there. With the support of the MedTech Accelerator, the company wants to expand their development of a new generation of Smart Nuclear Materials (SMN) and supporting technologies. Using a proprietary Isotope Searcher, Serva can identify all of the potential pathways to create any isotope, including those not currently utilized in nuclear medicine as well as those already in use.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
